| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland, November 4, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today provided a bu... |
| 30 Sep 2026 |
8-K: Other Events
On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the trea... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results |
| 15 Jul 2026 |
8-K: Other Events
On July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Share... |
| 25 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
Pre-Funded Warrants to Purchase up to 1,000,000 Ordinary Shares |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
© 2026 | Proprietary | MoonLake TX MoonLake Immunotherapeutics Investor Day June 22nd, 2026 |
| 09 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this MoonLake Immunotherapeutics 2022 Amended and Restated Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of Moon... |
| 01 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
On May 22, 2026, MoonLake Immunotherapeutics (the “Company”) entered into a Master Commercial Supply Agreement (the “Vetter MCSA”) with Vetter Pharma International GmbH (“Vetter”). Pursuant to the Vetter MCSA, Vetter, through Vetter Phar... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results |
| 23 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +4 more
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results |
| 08 Jan 2026 |
8-K: Other Events
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for Sonelokimab (SLK) in ... |
| 05 Nov 2025 |
8-K: Entry into a Material Definitive Agreement
MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Under... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab |
| 29 Sep 2025 |
8-K: Other Events
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its fi... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 5, 2025, MoonLake Immunotherapeutics (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “Annual Meeting”). As of the close of business on April 10, 2025, the record date for the Annual Meeting, th... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its fina... |
| 29 Apr 2025 |
8-K: Regulation FD Disclosure
On April 29, 2025, MoonLake Immunotherapeutics (the “Company”) will be posting to its website an investor presentation to be used in the Company’s April 29, 2025 Capital Markets Day event, including information regarding the Company’s fi... |
| 03 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today a... |
Loading...